(Circulation. 1999;99:3056-3062.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
From the Graduate Institute of Medical Sciences (J.-R.S., M.-C.M., Y.-C.K., C.-H.L.), the Department of Anatomy (C.-H.W.), Taipei Medical College; Institute of Life Sciences (W.-C.H.), Institute of Medical Sciences (M.-S.L.), the Department of Pharmacology (H.-N.L., M.-H.Y.), National Defense Medical Center, Taipei, Taiwan.
Correspondence to Dr Joen-Rong Sheu, Graduate Institute of Medical Sciences, Taipei Medical College, No. 250, Wu-Shing St, Taipei 110, Taiwan. E-mail sheujr{at}tmc.edu.tw
BackgroundThrombocytopenia frequently occurs early in the course of Gram-negative bacterial infections. Triflavin, an Arg-Gly-Aspcontaining disintegrin, has been suggested to interfere with the interaction of fibrinogen with the glycoprotein IIb/IIIa complex. The present study was undertaken to determine whether triflavin could prevent thrombocytopenia in lipopolysaccharide (LPS)-treated rats.
Methods and ResultsIn this study, 51Cr-labeled platelets were used to assess blood and tissue platelet accumulation after LPS challenge. The administration of LPS (4 mg/kg IV bolus) for 4 hours induced a reduction in radiolabeled platelets in blood and an obvious accumulation of platelets in liver. Triflavin (500 µg/kg) but not GRGDS (20 mg/kg) significantly prevented the alteration of radiolabeled platelet distribution in blood and liver when induced by LPS. Furthermore, triflavin but not GRGDS markedly suppressed the elevation in plasma thromboxane B2 concentration within the 4-hour period of LPS administration. In LPS-treated rats, the 5-hydroxytryptamine level was lower in the blood and higher in the liver compared with levels in normal salinetreated rats. Pretreatment with triflavin (500 µg/kg) significantly reversed the 5-hydroxytryptamine concentration in blood and liver of LPS-treated rats. In histological examinations and platelet adhesion assay, triflavin markedly inhibited the adhesion of platelets to subendothelial matrixes in vivo and in vitro.
ConclusionsThe results indicate that triflavin effectively prevents thrombocytopenia, possibly through the following 2 mechanisms: (1) Triflavin markedly inhibits platelet aggregation, resulting in decreased thromboxane A2 formation. (2) It inhibits the adhesion of platelets to subendothelial matrixes, thereby leading to a reversal in the distribution of platelets in blood and liver in LPS-treated rats.
Key Words: platelets platelet aggregation inhibitors peptides thromboxane
This article has been cited by other articles:
![]() |
G. Hsiao, J. J. Lee, K. H. Lin, C. H. Shen, T. H. Fong, D. S. Chou, and J. R. Sheu Characterization of a novel and potent collagen antagonist, caffeic acid phenethyl ester, in human platelets: In vitro and in vivo studies Cardiovasc Res, September 1, 2007; 75(4): 782 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Hsiao, K. H. Lin, Y. Chang, T. L. Chen, N. H. Tzu, D. S. Chou, and J. R. Sheu Protective Mechanisms of Inosine in Platelet Activation and Cerebral Ischemic Damage Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1998 - 2004. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Sheu, G. Hsiao, M. Y. Shen, Y. Wang, K. H. Lin, C. H. Lin, and D. S. Chou Inhibitory Mechanisms of Metallothionein on Platelet Aggregation in In Vitro and Platelet Plug Formation in In Vivo Experiments Experimental Biology and Medicine, December 1, 2003; 228(11): 1321 - 1328. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Aird The Hematologic System as a Marker of Organ Dysfunction in Sepsis Mayo Clin. Proc., July 1, 2003; 78(7): 869 - 881. [Abstract] [PDF] |
||||
![]() |
J. D. Guida, A. M. Kunig, K. H. Leef, S. E. McKenzie, and D. A. Paul Platelet Count and Sepsis in Very Low Birth Weight Neonates: Is There an Organism-Specific Response? Pediatrics, June 1, 2003; 111(6): 1411 - 1415. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Aird The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome Blood, May 15, 2003; 101(10): 3765 - 3777. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |